Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis

Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis

Atherosclerosis affects millions of people worldwide. However, the wide variety of limitations in the current therapeutic options leaves much to be desired in future lipid-lowering therapies. For example, although statins, which are the first-line treatment for coronary heart disease (CHD), reduce t...

Full description

Bibliographic Details
Main Authors:	Eftaxia-Konstantina Valanti, Katerina Dalakoura-Karagkouni, Despina Sanoudou
Format:	Article
Language:	English
Published:	MDPI AG 2018-10-01
Series:	Journal of Personalized Medicine
Subjects:	atherosclerosis lipoprotein metabolism reconstituted HDL apolipoprotein A-I apolipoprotein E
Online Access:	http://www.mdpi.com/2075-4426/8/4/34

Similar Items

Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux
by: Oktawia Nilsson, et al.
Published: (2021-01-01)

Evidence for differential effects of apoE3 and apoE4 on HDL metabolism
by: Paul C.R. Hopkins, et al.
Published: (2002-11-01)

Human Serum Amyloid a Impaired Structural Stability of High-Density Lipoproteins (HDL) and Apolipoprotein (Apo) A-I and Exacerbated Glycation Susceptibility of ApoA-I and HDL
by: Kyung-Hyun Cho
Published: (2022-07-01)

Defective functionality of HDL particles in familial apoA-I deficiency: relevance of alterations in HDL lipidome and proteome[S]
by: Fabiana Rached, et al.
Published: (2014-12-01)

Endothelial lipase is less effective at influencing HDL metabolism in vivo in mice expressing apoA-II
by: Uli C. Broedl, et al.
Published: (2006-10-01)

LDL-apheresis depletes apoE-HDL and pre-β1-HDL in familial hypercholesterolemia: relevance to atheroprotection
by: Alexina Orsoni, et al.
Published: (2011-12-01)

Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL
by: Irina N. Gorshkova, et al.
Published: (2023-02-01)

Significance of the hydrophobic residues 225–230 of apoA-I for the biogenesis of HDL1[S]
by: Panagiotis Fotakis, et al.
Published: (2013-12-01)

Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?
by: Eric J. Niesor
Published: (2015-01-01)

Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide <span style="font-variant: small-caps">d</span>-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice
by: Andrea Rivas-Urbina, et al.
Published: (2020-05-01)

Circulating HDL and Non-HDL Associated Apolipoproteins and Breast Cancer Severity
by: Christine Bobin-Dubigeon, et al.
Published: (2022-02-01)

Circulating HDL levels control hypothalamic astrogliosis via apoA-I
by: Anna Götz, et al.
Published: (2018-09-01)

Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I*
by: Brian J. Van Lenten, et al.
Published: (2008-11-01)

The Differential Effects of HDL Subpopulations on Lipoprotein Lipase (LPL)-Mediated VLDL Catabolism
by: Ewa Wieczorek, et al.
Published: (2021-12-01)

An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice
by: Shu-Chen Lu, et al.
Published: (2012-04-01)

Reconfiguring Nature’s Cholesterol Accepting Lipoproteins as Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents
by: Skylar T. Chuang, et al.
Published: (2020-05-01)

A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease
by: Alankrita Rani, et al.
Published: (2023-05-01)

On the hepatic mechanism of HDL assembly by the ABCA1/apoA-I pathway
by: Maki Tsujita, et al.
Published: (2005-01-01)

Role of the hydrophobic and charged residues in the 218–226 region of apoA-I in the biogenesis of HDL1[S]
by: Panagiotis Fotakis, et al.
Published: (2013-12-01)

Endogenous apoE expression modulates HDL3 binding to macrophages
by: Chen-Yi Lin, et al.
Published: (1998-02-01)

Alteration of negatively charged residues in the 89 to 99 domain of apoA-I affects lipid homeostasis and maturation of HDL[S]
by: Andreas K. Kateifides, et al.
Published: (2011-07-01)

High ApoB/ApoA-I Ratio Predicts Post-Stroke Cognitive Impairment in Acute Ischemic Stroke Patients with Large Artery Atherosclerosis
by: Minwoo Lee, et al.
Published: (2023-11-01)

Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally[S]
by: Mohamad Navab, et al.
Published: (2011-06-01)

Regulation of macrophage apoE secretion and sterol efflux by the LDL receptor
by: Danijela Lucic, et al.
Published: (2007-02-01)

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
by: Konstantina Georgila, et al.
Published: (2019-08-01)

Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins
by: Shucun Qin, et al.
Published: (2000-02-01)

ApoA-IV modulates the secretory trafficking of apoB and the size of triglyceride-rich lipoproteins
by: Richard B. Weinberg, et al.
Published: (2012-04-01)

HDL Composition, Heart Failure, and Its Comorbidities
by: Ahmed Diab, et al.
Published: (2022-03-01)

Strategies for consistent and automated quantification of HDL proteome using data-independent acquisition
by: Douglas Ricardo Souza Junior, et al.
Published: (2023-07-01)

Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle
by: Jonathan Dalla-Riva, et al.
Published: (2013-05-01)

Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changes1
by: David Masson, et al.
Published: (2006-02-01)

Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis
by: Ayiguli Abudukeremu, et al.
Published: (2021-08-01)

The ratio of HDL-C to apoA-I interacts with free triiodothyronine to modulate coronary artery disease risk
by: Li Li, et al.
Published: (2021-10-01)

Structural and Functional Changes of Reconstituted High-Density Lipoprotein (HDL) by Incorporation of α-synuclein: A Potent Antioxidant and Anti-Glycation Activity of α-synuclein and apoA-I in HDL at High Molar Ratio of α-synuclein
by: Kyung-Hyun Cho
Published: (2021-12-01)

Association of APOE genotype with carotid atherosclerosis in men and women
by: Roberto Elosua, et al.
Published: (2004-10-01)

ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity
by: Márcia Almeida Liz, et al.
Published: (2007-11-01)

In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions
by: Catherine C. Hedrick, et al.
Published: (2001-04-01)

Increased nonHDL cholesterol levels cause muscle wasting and ambulatory dysfunction in the mouse model of LGMD2B
by: Stephanie L. Sellers, et al.
Published: (2018-02-01)

ApoA-IMALLORCA impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia
by: Jesús M. Martín-Campos, et al.
Published: (2002-01-01)

Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia
by: Frank G. Schaap, et al.
Published: (2006-10-01)